abeomics

9853 Pacific Heights Blvd.
Suite D. San Diego,
CA 92121, USA
Tel: 858-263-4982
Email: info@abeomics.com

12-8004: Anti-Human HER-2 (Trastuzumab) – Dylight® 488

Clonality :	Monoclonal
Clone Name :	4D5-8
Application :	FACS
Reactivity :	Human
Alternative Name :	ErbB-2, NEU, NGL, HER2, TKR1, CD340, MLN 19, HER-2/neu
Isotype :	Human IgG1k
Immunogen Information :	Human epidermoid carcinoma cells (A431) over-expressing EGFR.

Description

Expression Host : HEK-293

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Trastuzumab. Clone 4D5-8 recognizes human erbB-2. This product is for research use only.

Trastuzumab is a monoclonal antibody targeting HER2, a 185 kDa transmembrane glycoprotein that contains an extracellular domain and intracellular tyrosine kinase activity. When it is functioning normally, the HER2 pathway supports cell growth and division. On the other hand, the over expression of HER2 propels cell growth beyond its typical range. This overexpression is associated with some cancers, namely breast and stomach, in which the HER2 protein can be expressed up to 100 times more than in typical cells. Trastuzumab induces an immune-mediated response that triggers the internalization and downregulation of HER2 making it an excellent target for immunotherapy. Several clinical studies are under way which show that anti-HER-2/neu antibodies inhibit the growth and proliferation of these tumor cells In vitro as well as In vivo.

Product Info

Amount :	100 µg
Content :	Concentration : 0.2 mg/ml This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage condition :	This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.

Application Note

The suggested concentration for Trastuzumab biosimilar antibody for staining cells in flow cytometry is <= 1.0 µg per 106 cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application.